Genmab A/S (NASDAQ:GMAB - Get Free Report) shares gapped up before the market opened on Wednesday . The stock had previously closed at $20.33, but opened at $20.87. Genmab A/S shares last traded at $20.78, with a volume of 155,920 shares trading hands.
Analysts Set New Price Targets
Several research analysts have weighed in on GMAB shares. Sanford C. Bernstein lowered Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Truist Financial reduced their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Finally, Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $39.17.
View Our Latest Analysis on Genmab A/S
Genmab A/S Stock Down 1.0%
The business has a 50-day simple moving average of $19.77 and a 200-day simple moving average of $20.67. The stock has a market cap of $13.34 billion, a P/E ratio of 11.96, a PEG ratio of 2.65 and a beta of 1.04.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. The firm had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Genmab A/S
Institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC grew its holdings in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after buying an additional 939 shares during the last quarter. Headlands Technologies LLC boosted its position in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after acquiring an additional 1,464 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in shares of Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after acquiring an additional 1,070 shares during the last quarter. Lindbrook Capital LLC grew its stake in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares during the last quarter. Finally, Barclays PLC increased its position in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after acquiring an additional 2,285 shares during the period. 7.07% of the stock is currently owned by institutional investors.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
